Intermonte

EL.EN.

OUTPERFORM

SECTOR: Industrials

Price (Eu):

41.85

Target Price (Eu):

53.00

+39-02-77115.318 Renato Gargiulo e-mail: renato.gargiulo@intermonte.it


Positive Momentum Ahead

- Quarterly top line growth better than expected, but operating profit basically in line. El.En. posted a stronger than projected 4Q15 sales growth of 11.3% YoY to Eu61.7mn (around 5% ahead of our forecast). By geographical area, quarterly revenues were mainly driven by Italy and markets outside Europe (benefiting from an improving business environment), but other European markets also performed positively. Both the main divisions posted positive performances, with industrial laser systems still achieving slightly higher growth than medical and aesthetic laser systems (again boosted by surgical applications). The higher sales were basically offset by slightly lower margins (partly due in our view to a different business mix), with a 4Q15 EBITDA of Eu6.4mn (vs. Eu6.5mn expected), corresponding to a margin of 10.3% (a slight dilution of around 50bps YoY). EBIT increased by 11% YoY to Eu5.3mn (bang in line), corresponding to a margin of 8.6% (approximately stable YoY). Pre-tax profit was instead ahead of estimates at Eu5.9mn (vs. Eu4.8mn expected), after better than projected net financial items. 2015 net income reached Eu14.4mn, additionally lifted by lower taxation. Net cash position (restated for Eu10.5mn of temporary financial investments booked as non-current assets) increased to Eu40.3mn (from Eu33.6mn at the end of September and slightly better than forecast). Finally, the Board proposed a dividend of Eu1.20 per share (vs. Eu1.00 expected).
- 2016 guidance: 5% YoY revenue growth. Estimates fine-tuned. On the back of the group's strong positioning and a favourable economic environment overall, the company provided a positive 2016 outlook, projecting a further top line increase of around 5% YoY (in line with our current estimate). On the other hand, the company's management gave more cautious (conservative, in our view) indications on full-year profitability, expecting 2016 EBIT broadly in line with 2015 (implying a margin dilution of around 50bps). Our updated forecast is for a flattish 2016 EBIT margin, leading to EBIT of Eu22.8mn (vs. Eu21.5mn in 2015). Following 4Q results and the company's indications, we have thus slightly reduced our 2016-17 profitability assumptions (by around 2% at the EBIT line), compensated at the bottom line level by a lower than previously expected tax rate.
- OUTPERFORM reiterated, target price increased to Eu53.0. We reiterate our positive stance on the stock as the company should continue to deliver top line growth this year, backed by an increasingly favourable economic environment and strong positioning in the medical and aesthetic treatment sectors. Successful penetration of the MonaLisa Touch product in the USA, and its effective introduction into new international markets, could lead to further upside on our estimates and, in our view, a stock re-rating. Our updated SOP valuation, which adds the value of El.En net of minorities to the market value of El.En's 4.4% stake in Cynosure, yields Eu53.0 per share (from Eu52.5 previously), with the change mainly the result of an updated valuation of the Cynosure stake.

Key Figures	2013A	2014A	2015A	2016E	2017E	
Sales (Eu mn)	157	180	218	229	239	Ī
Ebitda (Eu mn)	14	18	26	27	30	
Net profit (Eu mn)	6	17	14	14	16	
EPS - New (Eu)	1,260	2,290	2,979	2,888	3,251	
EPS - Old (Eu)		2,290	2,679	2,922	3,165	
DPS (Eu)	0,500	1,000	1,200	1,200	1,200	_
Ratios & Multiples	2013A	2014A	2015A	2016E	2017E	_
P/E	33,2	18,3	14,0	14,5	12,9	Ī
Div. Yield	1,2%	2,4%	2,9%	2,9%	2,9%	
EV/Ebitda	10,5	7,0	5,6	5,1	4,4	
ROCE	8,8%	14,2%	17,0%	15,0%	15,8%	

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.

EL.EN. - 12m Performance



RATING: Unchanged TARGET PRICE (Eu): from 52.50 to 53.00 2016E 2017E Change in EPS est: -1.2% 2.7%

STOCK DATA

Reuters code:			ELEIN.IVII
Bloomberg code:			ELN IM
Performance	1m	3m	12m
Absolute	9,8%	7,3%	16,1%
Relative	0,7%	16,5%	29,5%

12 months H/L: 45.70/33.50 SHARFHOI DER DATA No. of Ord. shares (mn): 5 Total No. of shares (mn): 5 Mkt Cap Ord (Eu mn): 202

Total Mkt Cap (Eu mn): 202 Mkt Float - ord (Eu mn): Mkt Float (in %): 44,7% Main shareholder: Cangioli Andrea 15,2%

90

BALANCE SHEET DATA 2016 Book value (Eu mn): 178 BVPS (Eu): 36,97 P/BV 1.1 Net Financial Position (Eu mn): 35 Enterprise value (Eu mn): 139

Please see important disclaimer on the last page of this report



N KEY FIGURES		2013A	2014A	2015A	2016E	2017
	Fiscal year end	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/201
PROFIT & LOSS (Eu mn)	Sales	157	180	218	229	23
	EBITDA	14	18	26	27	30
	EBIT	10	15	21	23	2
	Financial income (charges)	(1)	5	1	1	
	Associates & Others	2 11	4 24	0 23	0 23	2
	Pre-tax profit (Loss) Taxes	(4)	(6)	(7)		(8
	Taxes Tax rate (%)	-40,0%	-26,3%	-30,6%	(8) -33,2%	-30,99
	Minorities & discontinue activities	(0)	(1)	(2)	(2)	-30,77
	Net profit	6	17	14	14	1
	Total extraordinary items	.				
	Ebitda excl. extraordinary items	14	18	26	27	3
	Ebit excl. extraordinary items	10	14	21	23	2
	Net profit restated	4	11	14	14	1
PER SHARE DATA (Eu)	Total shares out (mn) - average fd	5	5	5	5	
. 1. 0	EPS stated fd	1,260	3,424	2,979	2,888	3,25
	EPS restated fd	1,260	2,290	2,979	2,888	3,25
	BVPS fd	26,588	29,632	35,287	36,975	39,02
	Dividend per share (ord)	0,500	1,000	1,200	1,200	1,20
	Dividend per share (sav)					
	Dividend pay out ratio (%)	39,7%	29,2%	40,3%	41,6%	36,9%
CASH FLOW (Eu mn)	Gross cash flow	9	21	20	20	2
	Change in NWC	4	(1)	(11)	(3)	(2
	Capital expenditure	(0)	(11)	(8)	(7)	(7
	Other cash items	0	0	0	0	
	Free cash flow (FCF)	10	9	2	10	1
	Acquisitions, divestments & others	(21)	19	(14)	0	(/
	Dividend Equity financing/Buy-back	(4) (4)	(3)	(5) 0	(6) 0	(6
	Change in Net Financial Position	(4)	25	(17)	5	
A	Total fixed assets	67	56	81	83	8
BALANCE SHEET (Eu mn)	Net working capital	48	50 50	60	63	6
	Long term liabilities	(3)	(2)	9	9	U
	Net capital employed	112	103	150	155	15
	Net financial position	22	47	30	35	4
	Group equity	134	151	180	189	20
	Minorities	6	8	9	11	1
	Net equity	128	143	170	178	18
TERPRISE VALUE (Eu mn)	Average mkt cap - current	202	202	202	202	20
TERRITOR VALUE (Editin)	Adjustments (associate & minorities)	35	29	29	29	2
	Net financial position	22	47	30	35	4
	Enterprise value	145	126	144	139	13
RATIOS(%)	EBITDA margin*	8,7%	10,0%	11,8%	12,0%	12,49
	EBIT margin*	6,1%	7,7%	9,9%	10,0%	10,39
	Gearing - Debt/equity	-16,2%	-31,3%	-16,6%	-18,2%	-21,09
	Interest cover on EBIT	8,1	nm	nm	nm	nn
	Debt/Ebitda	nm	nm	nm	nm	nr
	ROCE*	8,8%	14,2%	17,0%	15,0%	15,89
	ROE*	5,1%	12,2%	9,2%	8,0%	8,69
	EV/CE	1,3	1,2	1,1	0,9	0,
	EV/Sales	0,9	0,7	0,7	0,6	0,
	EV/Ebit	15,1	9,1	6,7	6,1	5,
	Free Cash Flow Yield	6,2%	5,2%	0,9%	6,0%	7,89
GROWTH RATES (%)	Sales	4,1%	14,4%	20,9%	5,2%	4,59
	EBITDA*	9,8%	30,7%	42,9%	6,8%	7,89
	EBIT*	28,2%	44,0%	55,8%	6,1%	8,59
	Net profit	-73,8%	171,7%	-13,0%	-3,1%	12,69
	EPS restated	93,6%	81,7%	30,1%	-3,1%	12,69

^{*} Excluding extraordinary items

Source: Intermonte SIM estimates

Results

El.En. Results

	(€ mn)	4Q14A	4Q15A	4Q15E	AVE	FY14A	FY15E
Sales		55,4	61,7	58,8	4,9%	180,0	217,7
	YoY growth %	10,1%	11,3%	6,1%			20,9%
EBITDA		6,0	6,4	6,5	-2,1%	18,0	25,7
	Ebitda margin %	10,8%	10,3%	11,0%		10,0%	11,8%
	YoY growth %	8,4%	5,9%	8,2%			42,9%
Total D&A		(1,2)	(1,1)	(1,2)		(2,7)	(4,2)
EBIT Adjusted	_	4,8	5,3	5,3	0,0%	13,8	21,5
	Ebit margin %	8,6%	8,6%	9,0%		7,7%	9,9%
EBIT		4,8	5,3	5,3	0,0%	15,3	21,5
	Ebit margin %	8,6%	8,6%	9,0%		8,5%	9,9%
	YoY growth %		11,2%	11,3%			40,5%
Net financials 8	& Participations	0,9	0,6	(0,5)		9,1	1,6
Pretax Profit Ac	djusted	5,7 5,7	5,9 5,9	4,8 4,8	23,1% 23,1%	18,4 24,4	23,1 23,1
Trotax From	Pretax margin %	10,2%	9,6%	8,2%	20,170	13,6%	10,6%
	YoY growth %	20,6%	4,6%	-15,1%		.6,676	-5,3%
Taxes						(6,4)	(7,1)
taxrate						-26,3%	-30,6%
Minorities and	disc. Operations					(1,5)	(1,7)
Adjusted Grou	p net profit					11,1	14,4
	YoY growth %						30,1%
Group net prof	it					16,5	14,4
•	YoY growth %						-21,8%
of w	hich non-recurrent						

Source: Company data and Intermonte Sim

Estimates

El.En. Change in estimates

(€ mn)		2015A	2016E	2017E
Sales new Sales old	% change	217,7	228,9 227,7 0,5%	239,1 239,1 0,0%
EBITDA new EBITDA old	% change	25,7	27,4 28,0 -2,1%	29,5 30,0 -1,5%
Adjusted EBIT new Adjusted EBIT old	% change	21,5	22,8 23,3 - 2,1%	24,7 25,1 -1,4%
Pretax Profit new Pretax Profit old	% change	23,1	23,3 23,8 -2,1%	25,3 25,7 -1,4%
Adjusted Group Net Adjusted Group Net	•	14,4	13,9 14,1 -1,2%	15,7 15,3 2,7%

Source: Company data and Intermonte Sim estimates





FL Fn.	Income	statement	estimates

(€ mn)	2012A	2013A	2014A	2015A	2016E	2017E	CAGR15-17E
Sales	151,2	157,4	180,0	217,7	228,9	239,1	4,8%
YoY growth %	10,1%	4,1%	14,4%	20,9%	5,2%	4,5%	
EBITDA	12,5	13,7	18,0	25,7	27,4	29,5	7,3%
Ebitda margin %	8,3%	8,7%	10,0%	11,8%	12,0%	12,4%	
YoY growth %	15,7%	9,8%	30,7%	42,9%	6,8%	7,8%	
Total D&A	(5,0)	(4,2)	(2,7)	(4,2)	(4,6)	(4,8)	
of which non-recurrent			1,5				
EBIT Reported	7,5	9,6	15,3	21,5	22,8	24,7	
Ebit margin %	4,9%	6,1%	8,5%	9,9%	10,0%	10,3%	
EBIT Adjusted	7,5	9,6	13,8	21,5	22,8	24,7	7,3%
Ebit margin %	4,9%	6,1%	7,7%	9,9%	10,0%	10,3%	
YoY growth %	46,7%	28,2%	44,0%	55,8%	6,1%	8,5%	
Net financial charges	(1,4)	(1,7)	4,6	1,6	0,5	0,6	
Other income		2,8	4,5				
of which non-recurrent		2,5	4,5				
Pretax Profit	6,1	10,7	24,4	23,1	23,3	25,3	4,7%
Taxes	(3,0)	(4,3)	(6,4)	(7,1)	(7,7)	(7,8)	
tax rate	-48,5%	-40,0%	-26,3%	-30,6%	-33,2%	-30,9%	
Income from continued op.	3,1	6,4					
Income from discontinued op.	26,7	0,0					
Net Profit before minority interest	29,8	6,4	18,0	16,0	15,6	17,5	4,5%
Minority interest from continued op	(1,0)	(0,3)	(1,5)	(1,7)	(1,6)	(1,8)	
Minority interest from discontinued	(5,6)	0,0					
Reported Group Net Profit	23,2	6,1	16,5	14,4	13,9	15,7	
	n.m.	-73,8%	171,7%	-13,0%	-3,1%	12,6%	
Adjusted Group Net Profit*	2,1	3,6	11,1	14,4	13,9	15,7	4,5%
		0.001			4 404		1
Net margin %	1,4%	2,3%	6,1%	6,6%	6,1%	6,6%	

Source: Company data and Intermonte SIM estimates

Valuation

El.En. - Valuation summary

	Method	€ mn	€ per share	previous (18/11/15)	change
El.En	DCF, net of min	220	45,5	45,4	0,1%
Stake in Cynosure	market value	36	7,5	7,0	6,3%
Total Equity Value		255,6	53,0	52,5	1,0%
El.En Share Price			41,9	43,9	-4,7%
potential upside			26,6%	19,5%	

Source: Intermonte Sim

EL.EN. Peer Group - Absolute Performances

Stock	Price	Ссу	Mkt cap	1M	3M	6M	YTD	1Y	2Y
EL.EN.	41,85	EUR	202	9,8%	7,3%	3,2%	4,1%	16,1%	110,3%
AMADA CO.		JPY	402.506	5,0%	-2,2%	10,3%	-3,1%	-0,4%	50,8%
COHERENT INC.		USD	2.054	10,5%	28,3%	47,6%	30,3%	28,3%	27,1%
CYMER		USD							
FIDIA	6,87	EUR	35	19,6%	12,3%	2,8%	7,7%	83,2%	109,2%
GSI GROUP		USD	446	4,5%	-6,4%	1,2%	-4,7%	-1,4%	2,9%
PRIMA INDUSTRIE	11,83	EUR	124	18,4%	-16,5%	-20,5%	-20,2%	-32,9%	-5,0%
ROFIN-SINAR TECH		USD	654	13,1%	-13,3%	-10,6%	-14,3%	-3,2%	-0,7%
Mean performance				11,6%	1,3%	4,9%	0,0%	12,8%	42,1%
Italy FTSE Mib	18.765,3	EUR	262.097	10,1%	-11,8%	-14,3%	-12,4%	-17,4%	-7,8%

Source: FactSet

EL.EN. Peer Group - Multiple Comparison

Stock	Price	Ccv	Mkt cap	EV/Sales	EV/Sales	EV/Ebitda	EV/Ebitda	EV/Ebit	EV/Ebit	P/E	P/E	Div Yield	Div Yield
SIUCK	Pilce	Ссу	wiki cap	2016	2017	2016	2017	2016	2017	2016	2017	2016	2017
EL.EN.	41,85	EUR	202	0,6	0,5	5,1	4,4	6,1	5,3	14,5	12,9	2,9%	2,9%
AMADA CO.	1128,00	JPY	402.506	1,3	1,2	8,0	7,9	9,7	9,5	15,4	16,1	3,0%	3,1%
COHERENT INC.	84,87	USD	2.054	2,2	2,1	11,4	10,1	14,9	12,6	21,8	19,0		
CYMER		USD											
FIDIA	6,87	EUR	35	0,5	0,4	6,5	5,2	8,6	6,7	18,1	10,4	0,0%	0,0%
GSI GROUP	12,98	USD	446							13,0	11,6		
PRIMA INDUSTRIE	11,83	EUR	124	0,6	0,5	6,3	4,8	10,7	7,4	14,5	9,2	2,1%	2,8%
ROFIN-SINAR TECH	22,94	USD	654	1,0	1,0	6,7	7,1	8,9	9,2	15,7	16,4	0,0%	0,0%
Median				1,0	1,0	6.7	7.1	9,7	9,2	15,5	13.9	1,1%	1,4%

Source: Intermonte SIM estimates for covered companies, FactSet consensus estimates for peer group

El.En. Peer Group - Absolute Performances

Stock	Price	Ссу	Mkt cap	1M	3M	6M	YTD	1Y	2Y
Cynosure	40,1	USD	921,5	14,5%	-1,7%	14,3%	-12,2%	32,5%	68,3%
El.En	41,9	Euro	201,9	9,8%	7,3%	3,2%	4,1%	16,1%	110,3%
Syneron Medical Ltd	6,9	USD	250,5	16,3%	-0,1%	-13,5%	-3,4%	-38,2%	-17,8%
Cutera, Inc.	10,3	USD	132,8	5,6%	-11,6%	-23,2%	-12,8%	-20,0%	37,7%
BIOLASE, Inc.	1,3	USD	73,9	76,8%	95,2%	-1,3%	63,9%	-33,2%	-39,3%
ZELTIQ Aesthetics, Inc.	22,3	USD	874,9	28,8%	-11,9%	-31,0%	-15,3%	-27,8%	71,8%
Medical avg				31,9%	17,9%	-17,3%	8,1%	-29,8%	13,1%
Italy FTSE Mib		•		10,4%	-9,6%	-10,9%	-10,7%	-13,0%	-7,6%

Source: Factset

El.En. Peer Group - Multiple Comparison

Stock	Price	Ссу	Mkt cap	EV/Sales 2016	EV/Sales 2017	P/E 2016	P/E 2017	EV/EBITDA 2016	EV/EBITDA 2017
El.En	41,9	EUR - Euro	201,9	0,6	0,5	14,5	12,9	5,1	4,4
Syneron Medical Ltd	6,9	USD	250,5	0,7	0,6	25,8	15,2		
Cynosure	40,1	USD	921,5	1,9	1,7	29,8	21,9	12,5	9,4
Cutera, Inc.	10,3	USD	132,8	0,9	0,9	27,8	19,3	19,1	21,7
BIOLASE, Inc.	1,3	USD	73,9	1,3	1,2				
ZELTIQ Aesthetics, Inc.	22,3	USD	874,9	2,9	2,5		46,1	30,4	15,3
Medical avg				1,3	1,2	27,8	20,6	19,1	15,3

Source: Factset consensus estimates for peer group, Intermonte estimates for El.En





DISCLAIMER (for more details go to http://intermonte.it/ disclosures.asp)

IMPORTANT DISCLOSURES

MPORTANT DISCLOSURES
The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by the Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermontes's website www.intermonte.it under DISCLOSURES. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question.

ANALYST CERTIFICATION

ANALYSI CERTIFICATION
For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securifies. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

CUIDE TO FUNDAMENTAL RESEARCH
Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY stock expected to outperform the market by over 25% over a 12 month period:

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period:

NEURAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period:

SELL: stock expected to underperform the market by between -10% and 25% over a 12 month period.

The stock price indicated is the reference price on the day prior to the publication of the report.

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms. As at 30 December 2015 Intermonte's Res Department covered 152 companies.

Intermonte's distribution of stock ratings is as follows BUY: 18.42% OUTPERFORM: 40.79% NEUTRAL: 35.18% UNDERPERFORM: 4.61% SELL: 1.32%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (38 in total) is as follows

BUY: 26.32% OUTPERFORM: 55 26% NEUTRAL: 18.42% UNDERPERFORM: 0.00% SELL: 0.00%

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

- o within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing (see companies indicated in bold type) an Institutional Offering and/or managed or co-managing or is co-managing (see companies in indicated in bold type) an Institutional Offering and/or managed or co-managing or is co-managin
- Intermonte SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following Companies: Aedes, Aeroporto di Bologna, Ascopiave, B&C Speakers, Banca Ifis, Banca Sistema, Banzai, Be, Bolzoni, BOMI, Carraro, Cattolica Assicurazioni, Cementir, Credito Valtellinese, Datalogic, DeA capital, DigiTouch, DigiTal bros, El.En, Emak, ERG, Ferrovie Nord Milano, Fintel Energia Group, Gefran, GreenItaly1, GO Internet, IGD, II Sole 24 Ore, IWB, Kinexia, Lucisano Media Group, LU VE, Mondo TV, OF Alpha Immobiliare, OF Beta Immobiliare, Recordati, Reno de Medici, Reply, Retelit, Saes Getters, Servizi Italia, Sesa, Snai, Tamburi Investment Partners, Tesmec, TBS Group, Tecnoinvestimenti, Ternienergia, TXT e-solutions, Vittoria Assicurazioni.
- Intermonte SIM acted as Global Coordinator in the GreenItaly1 IPO on the AIM Italia market and will receive a success fee if a business combination is approved by the shareholders. Intermonte SIM SpA and its subsidiaries do not hold a stake equal to or over 1% of common equity securities and/or warrants of any of the aforementioned subject companies, with the exception of: GreenItaly1.
- Intermonte SIM SpA has provided in the last 12 months / provides / may provide investment banking services to the following companies: Aedes, Conafi, CNRC/Marco Polo Industrial Holding (on Pirelli shares), Hitachi (on Ansaldo STS shares), Kinexia, Prelios, IPO Challenger/IWB.

DETAILS ON STOCKS RECOMMENDATION

Stock NAME	EL.EN.		
Current Recomm:	OUTPERFORM	Previous Recomm:	OUTPERFORM
Current Target (Eu):	53.00	Previous Target (Eu):	52.50
Current Price (Eu):	41.85	Previous Price (Eu):	44.10
Date of report:	16/03/2016	Date of last report:	18/11/2015

© Copyright 2010 by Intermonte SIM - All rights reserved
It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM. or are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONIE SIm strongly believes its research product on Italian equilies is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONIE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website www.intermonte.it/mifid